{
    "organizations": [],
    "uuid": "6d98e93468870f61ee05de67ead58291fb796490",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-h-lundbeck-says-fda-updates-trinte/brief-h-lundbeck-says-fda-updates-trintellix-label-to-include-data-showing-improvement-in-processing-speed-idUSASO00045O",
    "ord_in_thread": 0,
    "title": "BRIEF-H Lundbeck says FDA updates Trintellix label to include data showing improvement in processing speed",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2 (Reuters) - H Lundbeck A/S:\n* REG-FDA UPDATES TRINTELLIXÂ® (VORTIOXETINE) LABEL TO INCLUDE DATA SHOWING IMPROVEMENT IN PROCESSING SPEED, AN IMPORTANT ASPECT OF COGNITIVE FUNCTION IN ACUTE MAJOR DEPRESSIVE DISORDER (MDD)\n* U.S. FDA APPROVED A SUPPLEMENTAL NEW DRUG APPLICATION FOR TRINTELLIX (VORTIOXETINE)\n* FOCUS AND CONNECT STUDIES SHOW TRINTELLIX HAS A POSITIVE EFFECT ON PROCESSING SPEED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-03T04:49:00.000+03:00",
    "crawled": "2018-05-03T12:31:36.041+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "h",
        "lundbeck",
        "update",
        "vortioxetine",
        "label",
        "include",
        "data",
        "showing",
        "improvement",
        "processing",
        "speed",
        "important",
        "aspect",
        "cognitive",
        "function",
        "acute",
        "major",
        "depressive",
        "disorder",
        "mdd",
        "fda",
        "approved",
        "supplemental",
        "new",
        "drug",
        "application",
        "trintellix",
        "vortioxetine",
        "focus",
        "connect",
        "study",
        "show",
        "trintellix",
        "positive",
        "effect",
        "processing",
        "speed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}